Fibrotic cardiac remodeling ultimately leads to heart failure—a debilitating and costly
condition. Select antihypertensive agents have been effective in reducing or slowing the …

Background—Transient preceding brief ischemia provides potent cardioprotection against
subsequent long ischemia, termed ischemic preconditioning. Here, we hypothesized that …

Background Although effective in reducing blood pressure, therapy with a first-generation β-
blocker is currently controversial in metabolic syndrome due to its negative impact on …

Objectives: Increased sympathetic outflow, renin–angiotensin system (RAS) activity, and
oxidative stress are critical mechanisms underlying the adverse cardiovascular effects of …

Objectives D/L-Nebivolol is a lypophilic β 1-adrenergic antagonist which is devoid of intrinsic
sympathomimetic activity and can increase nitric oxide (NO) bioavailability with its …

Background and purpose: This study investigates the effect of pravastatin on blood pressure,
cardiovascular remodelling and impaired endothelial function induced as early signs of …

Asymmetric dimethylarginine (ADMA) has been reported to affect the synthesis of nitric oxide
(NO) in endothelial cells by inhibiting endothelial NO synthase (eNOS) activity and to cause …

Objective This study investigated the prophylactic effect of nebivolol against hyper-
homocysteinaemia (hHcy) induced oxidative stress in brain, heart, liver and kidney tissues …

Abstract β-Adrenergic blockers are no longer recommended as first-line therapy due to the
reduced cardioprotection of traditional β-blockers compared with other antihypertensive …

Angiotensin-converting enzyme inhibitors reduce blood pressure and attenuate cardiac and
vascular remodeling in hypertension. However, the kinetics of remodeling after …